Enterprise pharma is moving decisively toward direct-to-patient models. This is not a marketing trend or a side project. It is a structural response to access friction, pricing pressure, and the consumerization of healthcare. Patients are behaving more like consumers, distribution models are shifting, and manufacturers are being pulled closer to the patient experience whether they planned for it or not.
But there is a risk most organizations are underestimating. As direct-to-patient expands beyond lifestyle categories into specialty and complex chronic therapies, patient confusion becomes the limiting factor. Access wins do not translate into starts, persistence, or outcomes if patients do not understand what they have, what happens next, and why staying on therapy matters.
In a recent discussion, Bob Miglani, Founder and CEO of Hoot, and Jason Grossman, a pharma commercial leader with more than 25 years across oncology, hematology, and specialty launches, explored what is driving the shift and what enterprise patient services, market access, and brand teams should prioritize next.
The portfolio mix is forcing direct-to-patient to mature
The industry has moved from primary care scale blocks to specialty precision medicine. In many categories, diagnosis now requires molecular testing, more specialized interpretation, and more nuanced treatment decision-making. Guidelines have grown more complex. Treatment pathways have multiplied. As a result, time-to-therapy matters more, patient identification is harder, and education requirements are significantly higher than in past eras of “big drugs for big diseases.”
This changes the commercialization equation for enterprise teams. It is no longer enough to educate only the HCP and assume the patient journey will self-correct after the prescription. When the therapy is expensive, the disease is complex, and the steps are unfamiliar, the patient experience becomes the difference between a prescription written and a therapy started.
The bottleneck is no longer awareness. It is comprehension.
Pharma has invested for decades in omnichannel HCP engagement. The industry knows how to deliver the right message to the right clinician at the right time through the right channel. But the system breaks at the handoff from clinician to patient.
In most specialties, the clinician has limited time to deliver a diagnosis, explain testing and results, review options and tradeoffs, discuss side effects and monitoring, and initiate the access pathway through hubs, specialty pharmacies, and prior authorization requirements. Patients often walk out of that visit retaining fragments. That is not a critique of clinicians; it is a reality of time, emotion, and complexity.
Then decision-making moves to the home environment. This is where patients and caregivers try to make sense of what just happened, often late at night, often under stress, and often while balancing work, family, and fear. Increasingly, the dominant inputs are search, social feeds, peer communities, and AI-generated summaries. Those tools can help, but they can also amplify uncertainty because volume is not clarity, and speed is not trust.
This is how enterprise leakage shows up in the data. It appears as first-fill abandonment, early discontinuation, extended time-to-therapy, and inflated patient support costs that still fail to deliver the adherence needed for real-world impact.
Affordability pressure is accelerating direct-to-patient adoption
Direct-to-patient is growing in part because patients are actively shopping for affordability and convenience. The question is no longer only “What did my doctor prescribe?” It is also “Where can I get it?” and “What will it cost me?” That consumer behavior is now shaping adoption curves, especially as premiums rise and out-of-pocket costs remain unpredictable.
This shift is forcing manufacturers to evolve patient services beyond administrative access support into a broader enterprise capability. Direct-to-patient does not just change how therapy is delivered. It changes who owns the patient experience, who defines the success metrics, and how quickly a brand must respond to real-world friction.
Patient services is being redefined, but many programs are still incomplete
A key insight from the conversation was that many patient services models over-index on front-end access mechanics. Benefits investigations, prior authorizations, and financial assistance enrollment are essential. They remove major barriers and shorten time-to-therapy.
But they do not solve what happens after the patient gets the drug.
Once therapy begins, patients quickly encounter questions that determine whether they persist. They wonder what the drug is doing, what side effects are normal, what to do if something feels off, how to manage expectations over the first 30 to 90 days, and whether the discomfort or uncertainty they feel is a reason to stop. When those questions are not answered in a trusted way, patients delay, hesitate, and discontinue.
From an enterprise lens, this is not simply a patient experience issue. It directly affects gross-to-net performance and long-term revenue, because the cost of acquiring and supporting a patient is often incurred upfront, while the value is realized only if persistence follows.
The next enterprise advantage is physician-led education at scale
Patients do not want more reminders. They want guidance they trust, in language they can absorb, delivered when they are ready to absorb it. Trust is the currency, and the clinician relationship still carries the most weight.
The strategic shift is moving from messages that feel like they come from “the brand” to education that is anchored to the HCP relationship and extended beyond the visit. That does not mean adding more burden to clinicians. It means operationalizing clinician-led education in formats that fit the patient’s life, at home, after diagnosis, and throughout the first critical stages of therapy.
When done well, this closes the gap between clinic and kitchen table. It reduces fear-based discontinuation. It makes the next steps clear. It prevents misinformation from becoming the default narrative. It also improves the quality of the patient’s questions at the next visit, which strengthens the clinician’s ability to guide care in limited time.
Two-way engagement becomes enterprise intelligence
One of the biggest missed opportunities in traditional adherence programs is that they often push information in one direction. They remind, they nudge, they notify, and they rarely learn.
The enterprise advantage emerges when patient engagement becomes two-way. It can be as simple as asking whether a patient is refilling and, if not, capturing why. At scale, that becomes a live view of the real reasons patients drop, segmented by cohort, therapy type, and phase of the journey.
That insight is not just useful for patient services. It becomes continuous market intelligence for brand, market access, and field strategy. It reveals where education is failing, where expectations are misaligned, and where operational friction is quietly eroding performance.
What enterprise teams should prioritize this year
As direct-to-patient scales, the winners will be the organizations that treat patient comprehension as a core KPI, not a nice-to-have. Patient understanding is the prerequisite for starts and persistence. If comprehension is unmanaged, confusion will become the default, and abandonment will look like an “access problem” even when the root cause is education and trust.
The second priority is extending the physician’s voice beyond the visit. Patient trust is still anchored to clinicians. The enterprise opportunity is to deliver clinician-led education at scale without demanding more clinician time.
The third priority is building two-way engagement loops that convert patient communication into measurable insight. If you can capture why patients hesitate, delay, or discontinue, you can address those barriers with precision rather than generic outreach.
The bottom line
Direct-to-patient is expanding. Specialty complexity is rising. AI and social inputs are accelerating patient confusion. Enterprise pharma cannot assume that improved access alone will translate into improved outcomes or stronger brand performance.
Direct-to-patient will only deliver its promise if it is paired with trusted education and ongoing engagement that meets patients where decisions actually happen. For most therapies, that is not in the exam room. It is at home, after the visit, when the patient is trying to make sense of what comes next.